Tradr Announces Liquidation of CLSZ, HLXX, MSQ & SRPU

The sole news release, dated May 22, 2026, states that Tradr ETFs has approved the liquidation of four exchange-traded funds, including SRPU (Tradr 2X Long SRPT Daily ETF). The final trading day for SRPU on Cboe BZX will be June 11, 2026. The fund will cease operations and liquidate all assets on or about June 18, 2026, and proceeds will be distributed to shareholders of record.

The liquidation announcement is unequivocally negative for SRPU shareholders. The fund is being wound down, which means the investment vehicle itself will cease to exist. This is not a corporate action like a merger or dividend; it is a terminal event. The proximate cause is almost certainly poor fund performance and/or insufficient assets under management to sustain operations. The price chart over the past eight months shows a catastrophic decline from nearly $30 to under $7, reflecting both the decay of a daily leveraged product in a volatile underlying (Sarepta Therapeutics) and potential large redemptions. The forced closure will crystallize losses for all remaining holders. The final distribution amount is unknown but will likely equal the net asset value (NAV) per share at liquidation, less fees and expenses. Given the fund’s dire price action, the NAV is almost certainly far below the levels seen just a few months ago, and may even be below the current market price if the liquidation triggers a final drawdown. In any case, the news confirms that there is no future recovery opportunity; the ETF is ending.

SRPU is an exchange-traded fund, not an operating company. It is a 2x daily leveraged ETF that seeks to deliver twice the daily performance of Sarepta Therapeutics Inc. (SRPT). It does not have a flagship project, properties, or revenues; it is a derivative-based investment product. The underlying company, Sarepta Therapeutics, is a biopharmaceutical firm focused on genetic medicine for rare diseases.